Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard Chemotherapy in Ovarian Cancer
NCT00004921Phase 3Completed
- Sponsor
- EBMT Solid Tumors Working Party
- Start
- Sep 1998
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of cyclophosphamide and melphalan in ovarian cancer (2 arms), sponsored by EBMT Solid Tumors Working Party. Primary endpoint: Progression-Free Survival at 2 years. Started Sep 1998; status: completed.
02
Drugs
cyclophosphamidemelphalan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00004921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004921.